Histone Acyl Code in Precision Oncology: Mechanistic Insights from Dietary and Metabolic Factors

Overview

Journal Nutrients

Date 2024 Feb 10

PMID 38337680

Authors

Sultan Neja

Wan Mohaiza Dashwood

Roderick H Dashwood

Praveen Rajendran

Affiliations

Soon will be listed here.

Abstract

Cancer etiology involves complex interactions between genetic and non-genetic factors, with epigenetic mechanisms serving as key regulators at multiple stages of pathogenesis. Poor dietary habits contribute to cancer predisposition by impacting DNA methylation patterns, non-coding RNA expression, and histone epigenetic landscapes. Histone post-translational modifications (PTMs), including acyl marks, act as a molecular code and play a crucial role in translating changes in cellular metabolism into enduring patterns of gene expression. As cancer cells undergo metabolic reprogramming to support rapid growth and proliferation, nuanced roles have emerged for dietary- and metabolism-derived histone acylation changes in cancer progression. Specific types and mechanisms of histone acylation, beyond the standard acetylation marks, shed light on how dietary metabolites reshape the gut microbiome, influencing the dynamics of histone acyl repertoires. Given the reversible nature of histone PTMs, the corresponding acyl readers, writers, and erasers are discussed in this review in the context of cancer prevention and treatment. The evolving 'acyl code' provides for improved biomarker assessment and clinical validation in cancer diagnosis and prognosis.

Citing Articles

Epigenetic regulation of transcription factors involved in NLRP3 inflammasome and NF-kB signaling pathways.

Kaszycki J, Kim M Front Immunol. 2025; 16:1529756.

PMID: 40046056 PMC: 11879833. DOI: 10.3389/fimmu.2025.1529756.

Post-Translational Modifications of Proteins Orchestrate All Hallmarks of Cancer.

Bruno P, Arshad A, Gogu M, Waterman N, Flack R, Dunn K Life (Basel). 2025; 15(1).

PMID: 39860065 PMC: 11766951. DOI: 10.3390/life15010126.

References

Kang Y, Nian H, Rajendran P, Kim E, Dashwood W, Pinto J . HDAC8 and STAT3 repress BMF gene activity in colon cancer cells. Cell Death Dis. 2014; 5:e1476. PMC: 4237248. DOI: 10.1038/cddis.2014.422. View

Khochbin S, Verdel A, Lemercier C . Functional significance of histone deacetylase diversity. Curr Opin Genet Dev. 2001; 11(2):162-6. DOI: 10.1016/s0959-437x(00)00174-x. View

Pan L, Feng F, Wu J, Fan S, Han J, Wang S . Demethylzeylasteral targets lactate by inhibiting histone lactylation to suppress the tumorigenicity of liver cancer stem cells. Pharmacol Res. 2022; 181:106270. DOI: 10.1016/j.phrs.2022.106270. View

Merzvinskyte R, Treigyte G, Savickiene J, Magnusson K, Navakauskiene R . Effects of histone deacetylase inhibitors, sodium phenyl butyrate and vitamin B3, in combination with retinoic acid on granulocytic differentiation of human promyelocytic leukemia HL-60 cells. Ann N Y Acad Sci. 2007; 1091:356-67. DOI: 10.1196/annals.1378.080. View

Chen Q, Yang B, Liu X, Zhang X, Zhang L, Liu T . Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents. Theranostics. 2022; 12(11):4935-4948. PMC: 9274749. DOI: 10.7150/thno.73223. View

Warburg O, Wind F, Negelein E . THE METABOLISM OF TUMORS IN THE BODY. J Gen Physiol. 2009; 8(6):519-30. PMC: 2140820. DOI: 10.1085/jgp.8.6.519. View

Farooqi A, Fayyaz S, Poltronieri P, Calin G, Mallardo M . Epigenetic deregulation in cancer: Enzyme players and non-coding RNAs. Semin Cancer Biol. 2020; 83:197-207. DOI: 10.1016/j.semcancer.2020.07.013. View

Morrison A . Cancer cell metabolism connects epigenetic modifications to transcriptional regulation. FEBS J. 2021; 289(5):1302-1314. PMC: 8613311. DOI: 10.1111/febs.16032. View

Singh B, Zhang G, Hwa Y, Li J, Dowdy S, Jiang S . Nonhistone protein acetylation as cancer therapy targets. Expert Rev Anticancer Ther. 2010; 10(6):935-54. PMC: 3273412. DOI: 10.1586/era.10.62. View

10.

Li Y, Seto E . HDACs and HDAC Inhibitors in Cancer Development and Therapy. Cold Spring Harb Perspect Med. 2016; 6(10). PMC: 5046688. DOI: 10.1101/cshperspect.a026831. View

11.

Hitosugi T, Kang S, Vander Heiden M, Chung T, Elf S, Lythgoe K . Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal. 2009; 2(97):ra73. PMC: 2812789. DOI: 10.1126/scisignal.2000431. View

12.

Yoon S, Eom G . HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases. Chonnam Med J. 2016; 52(1):1-11. PMC: 4742605. DOI: 10.4068/cmj.2016.52.1.1. View

13.

Garcia-Gimenez J, Garces C, Roma-Mateo C, Pallardo F . Oxidative stress-mediated alterations in histone post-translational modifications. Free Radic Biol Med. 2021; 170:6-18. DOI: 10.1016/j.freeradbiomed.2021.02.027. View

14.

Stoffel E, Murphy C . Epidemiology and Mechanisms of the Increasing Incidence of Colon and Rectal Cancers in Young Adults. Gastroenterology. 2019; 158(2):341-353. PMC: 6957715. DOI: 10.1053/j.gastro.2019.07.055. View

15.

Pavlova N, Thompson C . The Emerging Hallmarks of Cancer Metabolism. Cell Metab. 2016; 23(1):27-47. PMC: 4715268. DOI: 10.1016/j.cmet.2015.12.006. View

16.

Bakhshi T, Way T, Muncy B, Georgel P . Effects of the omega-3 fatty acid DHA on histone and p53 acetylation in diffuse large B cell lymphoma. Biochem Cell Biol. 2023; 101(2):172-191. DOI: 10.1139/bcb-2022-0288. View

17.

Baylin S, Jones P . Epigenetic Determinants of Cancer. Cold Spring Harb Perspect Biol. 2016; 8(9). PMC: 5008069. DOI: 10.1101/cshperspect.a019505. View

18.

Kespohl M, Vachharajani N, Luu M, Harb H, Pautz S, Wolff S . The Microbial Metabolite Butyrate Induces Expression of Th1-Associated Factors in CD4 T Cells. Front Immunol. 2017; 8:1036. PMC: 5581317. DOI: 10.3389/fimmu.2017.01036. View

19.

Waddell A, Huang H, Liao D . CBP/p300: Critical Co-Activators for Nuclear Steroid Hormone Receptors and Emerging Therapeutic Targets in Prostate and Breast Cancers. Cancers (Basel). 2021; 13(12). PMC: 8229436. DOI: 10.3390/cancers13122872. View

20.

Liu Z, Ren Y, Weng S, Xu H, Li L, Han X . A New Trend in Cancer Treatment: The Combination of Epigenetics and Immunotherapy. Front Immunol. 2022; 13:809761. PMC: 8818678. DOI: 10.3389/fimmu.2022.809761. View